ARTICLE | Clinical News
PA-457: Phase I data
July 19, 2004 7:00 AM UTC
Previously reported results from a placebo-controlled Phase I trial in 26 uninfected healthy male volunteers showed that PA-457 was well tolerated at doses of 25 mg, 50 mg, 100 mg or 250 mg. All doses...